 "Dishman Pharma gains post clarification on Clovis issue")
Dishman Pharmaceuticals and Chemicals is trading higher by 5% at Rs 341 on the National Stock Exchange (NSE) after the company has clarified that it has not received any warning from the United States Food and Drug Administration (USFDA) on Clovis issue.
The stock has hit a high of Rs 345 in an intra-day trade and has seen a combined 2.7 million shares changed hands on the counter on the NSE and BSE.
On Tuesday, the stock tanked 14% on news reports that USFDA gives warning letter to Dishman due to Clovis issues.
“The company has not received any USFDA warnings or any communication whatsoever due to Clovis Issue” Dishman Pharma said in a regulatory filing.
Recent news item which appeared in the website-www.moneycontrol.com/ET Now/CNBC dated 17-Nov-2015 are basically with related to Clovis Oncology only and it has not relevance with our company, it added.
The stock has hit a high of Rs 345 in an intra-day trade and has seen a combined 2.7 million shares changed hands on the counter on the NSE and BSE.
On Tuesday, the stock tanked 14% on news reports that USFDA gives warning letter to Dishman due to Clovis issues.
“The company has not received any USFDA warnings or any communication whatsoever due to Clovis Issue” Dishman Pharma said in a regulatory filing.
Recent news item which appeared in the website-www.moneycontrol.com/ET Now/CNBC dated 17-Nov-2015 are basically with related to Clovis Oncology only and it has not relevance with our company, it added.
